$NeuroSense Therapeutics (NRSN.US)$NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) on Wednesday said it is currently in advanced discussions with several multi-billion-dollar pharmaceutical companies regarding a potential strategic partnership to develop and commercialize its lead drug candidate, PrimeC, for Amyotrophic Lateral Sclerosis (ALS). These discussions, based on non-binding terms, indicate the potential for substantial financial benefits to NeuroSense, including upfront payments, mile...
NeuroSense Therapeutics股票讨论区
Neurosense Therapeutics获得重要的美国专利,用于ALS和阿尔茨海默病的主力资产Novel Primec配方
These discussions, based on non-binding terms, indicate the potential for substantial financial benefits to NeuroSense, including upfront payments, mile...
NeuroSense Therapeutics有限公司(纳斯达克:NRSN)(“NeuroSense”)该晚期临床阶段生物技术公司以开发治疗严重神经退行性疾病的新型疗法而闻名,最近宣布了其PARADIGM(第IIb期)研究的积极12个月铁生物标志物数据。该研究评估了安全性和疗效...
Neurosense Therapeutics宣布ALS第20亿临床试验的阳性生物标志物数据
暂无评论